RL

Relay Therapeutics IncNASDAQ RLAY Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

1.184

Small

Exchange

XNAS - Nasdaq

RLAY Stock Analysis

RL

Uncovered

Relay Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-6/100

Low score

Market cap $B

1.184

Dividend yield

Shares outstanding

121.39 B

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 327 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.

View Section: Eyestock Rating